10
Jul
2020
The Remdesivir Pricing Letter Gilead Should Have Written
Dear America, We’ve decided to grossly underprice remdesivir. Hundreds of thousands of COVID-19 patients in America, and even more around the world, need our drug. But the US insurance system is corrupt and heartless. It has demonstrated that it will go to great lengths to prevent patients from getting appropriate, physician-prescribed treatments. You know their tricks: high deductibles, high copays,...Read More
29
Mar
2020
COVID-19 Teaches Us the Real Definition of a ‘Novel’ Drug
Will the world care how we beat COVID-19 – whether with a drug we make from scratch or an older one that turns out to get the job done? As people concerned for our families, we all know the answer. Just get it done! But as drug developers, let’s be honest that it doesn’t feel quite as heroic unless it’s...Read More
22
Jan
2020
False Heroes: Pharmacy Benefit Managers and the Patients They Prey On
[Editor’s Note: this is an excerpt from “The Great American Drug Deal.” The book is now available on Amazon.] By Peter Kolchinsky It’s hard to know when actual prices for a particular drug really do go up, because there is so little transparency in pricing. A lot of the public discourse on pricing is based on “list prices,” which no...Read More